1. Academic Validation
  2. Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss

Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss

  • Cancer Invest. 2021 May;39(5):423-434. doi: 10.1080/07357907.2021.1899200.
Yao Fan 1 2 Hui Fan 2 Zhen Quan 1 XiaoHou Wu 1
Affiliations

Affiliations

  • 1 Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • 2 Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, Chongqing Medical University, Chongqing, China.
Abstract

Tumor suppressor genes RB1 and TP53 are altered frequently in prostate Cancer (PC), whether RB1 and TP53 inactivation promotes radioresistance remains unclear. Herein, we demonstrated that RB1 loss enhanced ionizing radiation (IR)-induced DNA damage to inhibit cell proliferation and promote cellular senescence through a TP53-dependent pathway in LNCaP cells. Furthermore, the stabilization of TP53 was regulated by ATM-mediated phosphorylation of MDM2 at Ser395. However, inactivation of RB1/TP53 reversed DNA damage-induced cellular senescence and promoted radiation survival. Importantly, combined with PARP1 Inhibitor restored radiosensitivity. This finding provides a potential approach for the therapy of PC with RB1/TP53 inactivation.

Keywords

PARP1; Prostate cancer; RB1; TP53; radioresistance.

Figures
Products